Honigman Miller Schwartz and Cohn LLP
08/04/2026 | Press release | Distributed by Public on 08/04/2026 12:27
Announcement | Aug 4, 2026Honigman Represents Catalio Capital Management in Claris Biotherapeutics’ $118 Million Series B Financing
Honigman recently represented Catalio Capital Management, a health care-focused investment firm, in connection with Claris Biotherapeutics' $118 million Series B financing.
Claris Biotherapeutics is a biotechnology company developing therapies for limbal stem cell deficiency (LSCD), an eye disease caused by damage or loss of corneal stem cells that can lead to vision loss or blindness. The Series B financing was co-led by Samsara Biocapital and Catalio Capital Management.
The Honigman team was led by Corporate Partners Phillip D. Torrence and Rachel Rhodes.
Honigman Miller Schwartz and Cohn LLP published this content on August 04, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 04, 2026 at 18:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]